Zelluna Doses First Solid Tumor Patient in Phase 1 Trial of MAGE-A4-Targeting Therapy — Zelluna ASA

Event summary

Zelluna dosed the first solid tumor patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation Trust.
ZI-MA4-1 is the world’s first MAGE-A4-targeting TCR-NK therapy in clinical development.
The study is active at two UK sites: The Christie and The Royal Marsden NHS Foundation Trusts.
Initial clinical data from the ZIMA-101 study expected from mid-2026.

The big picture

Zelluna’s dosing of the first patient with its proprietary TCR-NK therapy marks a critical step in validating its platform for treating advanced solid tumors. The trial’s success could position Zelluna as a key player in the rapidly evolving cell therapy space, particularly if it addresses current limitations in targeting and scalability. The focus on MAGE-A4, a target present in several common cancers, underscores the potential market opportunity.

What we're watching

Clinical Progress: The pace at which Zelluna advances the ZIMA-101 trial and generates initial clinical data will determine its near-term valuation.
Therapeutic Efficacy: Whether ZI-MA4-1 demonstrates sufficient safety and preliminary anti-tumor activity to justify further development.
Market Differentiation: How Zelluna’s TCR-NK platform compares against competing solid tumor therapies in terms of scalability and precision targeting.